ECSP14014778A - Composiciones derivadas de la quitosana - Google Patents

Composiciones derivadas de la quitosana

Info

Publication number
ECSP14014778A
ECSP14014778A ECIEPI201414778A ECPI201414778A ECSP14014778A EC SP14014778 A ECSP14014778 A EC SP14014778A EC IEPI201414778 A ECIEPI201414778 A EC IEPI201414778A EC PI201414778 A ECPI201414778 A EC PI201414778A EC SP14014778 A ECSP14014778 A EC SP14014778A
Authority
EC
Ecuador
Prior art keywords
chitosane
compositions derived
neoplasms
malignant neoplasms
derived
Prior art date
Application number
ECIEPI201414778A
Other languages
English (en)
Inventor
Carubelli Raoul
Hode Tomas
Alleruzzo Luciano
Waynant Kristopher
E Nordquist Robert
Jenkins Peter
R Chen Wei
Raker Joe
Original Assignee
Immunophotonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14014778(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunophotonics Inc filed Critical Immunophotonics Inc
Publication of ECSP14014778A publication Critical patent/ECSP14014778A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Electromagnetism (AREA)
  • Otolaryngology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención está relacionada en general con los compuestos farmacéuticos que comprenden compuestos derivados de quitosana empleados para el tratamiento de neoplasmas, como por ejemplo, neoplasmas malignos del pulmón, tiroides y riñón, y otros tipos de neoplasmas malignos, y otros trastornos médicos.
ECIEPI201414778A 2012-01-20 2014-08-19 Composiciones derivadas de la quitosana ECSP14014778A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261588783P 2012-01-20 2012-01-20

Publications (1)

Publication Number Publication Date
ECSP14014778A true ECSP14014778A (es) 2016-01-29

Family

ID=48799808

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201414778A ECSP14014778A (es) 2012-01-20 2014-08-19 Composiciones derivadas de la quitosana

Country Status (31)

Country Link
US (1) US20150018748A1 (es)
EP (2) EP3831393A1 (es)
JP (1) JP6180436B2 (es)
KR (5) KR20220028153A (es)
CN (2) CN104619310A (es)
AU (1) AU2013209716B2 (es)
BR (1) BR112014017426B1 (es)
CA (1) CA2861367C (es)
CL (1) CL2014001880A1 (es)
CO (1) CO7101239A2 (es)
CY (1) CY1123490T1 (es)
DK (1) DK2804611T3 (es)
EA (1) EA030148B1 (es)
EC (1) ECSP14014778A (es)
ES (1) ES2829899T3 (es)
HK (1) HK1210019A1 (es)
HR (1) HRP20201647T1 (es)
HU (1) HUE051744T2 (es)
IL (1) IL233649B (es)
LT (1) LT2804611T (es)
MX (1) MX371275B (es)
MY (1) MY191932A (es)
NZ (1) NZ628433A (es)
PE (1) PE20142325A1 (es)
PL (1) PL2804611T3 (es)
PT (1) PT2804611T (es)
RS (1) RS61257B1 (es)
SG (1) SG11201403943TA (es)
SI (1) SI2804611T1 (es)
SM (1) SMT202000637T1 (es)
WO (1) WO2013109732A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US20190002594A1 (en) * 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
CN107200788B (zh) * 2017-05-11 2020-04-14 暨南大学 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
US20200010575A1 (en) 2018-07-05 2020-01-09 Immunophotonics, Inc. Semi-synthetic biopolymers for use in treating proliferative disorders
WO2020060131A1 (ko) * 2018-09-19 2020-03-26 주식회사 엘지화학 LiOH를 포함하는 리튬 이차 전지용 전극, 그의 제조방법, 및 상기 전극을 포함하는 리튬 이차 전지
CN113194991B (zh) 2018-11-26 2024-09-24 四十七公司 针对c-kit的人源化抗体
KR20220004077A (ko) 2019-05-02 2022-01-11 스티밋 코퍼레이션 암 치료
GB202007703D0 (en) * 2020-05-22 2020-07-08 Nanomerics Ltd Amphiphilic carbohydrate compounds
US20250134993A1 (en) * 2021-08-27 2025-05-01 Immunophotonics, Inc. Glycated chitosans for treatment of viral infections
AU2023413677A1 (en) 2022-12-20 2025-06-19 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide
KR20250122523A (ko) 2022-12-20 2025-08-13 리틱스 바이오파마 에이에스 종양 용해성 펩티드 및 키토산을 포함하는 조성물
CN117820043A (zh) * 2023-03-21 2024-04-05 广州优卡思农业技术有限公司 一种龙虾壳水溶性肥料及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US591200A (en) 1897-10-05 Safe-lock
US4424346A (en) * 1981-06-04 1984-01-03 Canadian Patents And Development Ltd. Derivatives of chitins, chitosans and other polysaccharides
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5283225A (en) 1992-11-24 1994-02-01 Eastman Kodak Company Underlayer of dye-donor element for thermal dye transfer systems
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
JP3929491B2 (ja) * 1995-04-04 2007-06-13 ウーンド・ヒーリング・オブ・オクラホマ・インコーポレーテッド イムノアジュバントを併用する光力学療法による癌治療
US6316007B1 (en) * 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
DE69938612T2 (de) * 1998-11-10 2009-07-09 Netech Inc., Kawasaki Funktionelle chitosanderivate
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
US6756363B1 (en) * 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
CN101855248B (zh) * 2007-11-13 2012-08-22 生物技术通用（以色列）有限公司 用于粘弹性生物聚合物的稀释过滤灭菌方法
CN101440136B (zh) * 2008-12-12 2011-07-06 中国海洋大学 胺糖化几丁聚糖复合物的制备方法

Also Published As

Publication number Publication date
BR112014017426A8 (pt) 2017-07-04
EP3831393A1 (en) 2021-06-09
WO2013109732A2 (en) 2013-07-25
CA2861367C (en) 2021-06-29
KR20140117487A (ko) 2014-10-07
NZ628433A (en) 2017-02-24
KR20180123727A (ko) 2018-11-19
CY1123490T1 (el) 2022-03-24
HRP20201647T1 (hr) 2021-06-25
BR112014017426A2 (pt) 2017-06-13
CL2014001880A1 (es) 2014-11-07
IL233649B (en) 2019-07-31
HUE051744T2 (hu) 2021-03-29
MX2014008702A (es) 2015-04-08
SMT202000637T1 (it) 2021-01-05
EP2804611A4 (en) 2016-02-17
JP2015513522A (ja) 2015-05-14
SI2804611T1 (sl) 2021-01-29
KR20200139254A (ko) 2020-12-11
IL233649A0 (en) 2014-08-31
MY191932A (en) 2022-07-19
US20150018748A1 (en) 2015-01-15
MX371275B (es) 2020-01-23
LT2804611T (lt) 2020-11-25
PT2804611T (pt) 2020-11-12
EA201491402A1 (ru) 2014-12-30
AU2013209716B2 (en) 2017-04-27
WO2013109732A3 (en) 2015-01-08
CA2861367A1 (en) 2013-07-25
PL2804611T3 (pl) 2021-03-08
AU2013209716A1 (en) 2014-08-28
EP2804611B1 (en) 2020-09-30
HK1210019A1 (en) 2016-04-15
CN104619310A (zh) 2015-05-13
ES2829899T3 (es) 2021-06-02
CN110038125A (zh) 2019-07-23
CO7101239A2 (es) 2014-10-31
BR112014017426B1 (pt) 2021-12-28
RS61257B1 (sr) 2021-01-29
SG11201403943TA (en) 2014-08-28
PE20142325A1 (es) 2015-02-01
KR20220028153A (ko) 2022-03-08
EP2804611A2 (en) 2014-11-26
DK2804611T3 (da) 2020-11-09
JP6180436B2 (ja) 2017-08-16
EA030148B1 (ru) 2018-06-29
KR20170032490A (ko) 2017-03-22

Similar Documents

Publication Publication Date Title
ECSP14014778A (es) Composiciones derivadas de la quitosana
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
PH12016501151A1 (en) Nrf2 regulators
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
CR20150326A (es) Inhibidores de autotaxina
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CR20150316A (es) Compuestos y sus métodos de empleo
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
GT201500247A (es) Imidazopiridazinas sustituidas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
PH12014502032A1 (en) Treatment of brain cancer
CL2015002027A1 (es) Compuestos quimicos